Join the Repatha Pushtronex group to help and get support from people like you.
Repatha Pushtronex News
FDA Approves Repatha (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia
THOUSAND OAKS, Calif., Sept. 24, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha® (evolocumab) as an adjunct to diet and ...
Amgen Makes Repatha (Evolocumab) Available in the U.S. at a 60 Percent Reduced List Price
THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that it is making Repatha (evolocumab), an innovative biologic medicine for people with high cholesterol who...
FDA Approves Amgen's Repatha (evolocumab) to Prevent Heart Attack and Stroke
THOUSAND OAKS, Calif., Dec. 1, 2017 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug...
Further information
Related condition support groups
High Cholesterol - Familial Heterozygous, Cardiovascular Risk Reduction, High Cholesterol - Familial Homozygous, High Cholesterol